Regencell Bioscience Holdings Ltd (RGC) Financial Statements
Source: SEC EDGAR filings · read by EquiReason
RGCRegencell Bioscience Holdings LtdFollow RGC — free
—
Price chart with a free account
- Market cap
- 3.8B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 28 Oct, in 4 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters.
| Line | FY2021 Jun 21 | FY2022 Jun 22 | FY2023 Jun 23 | FY2024 Jun 24 | FY2025 Jun 25 | FY2026 Jun 26 | TTM | Trend |
|---|---|---|---|---|---|---|---|---|
| Research & development | 0.4 | 2.5 | 1.6 | 1.1 | 0.9 | 1.3 | — | |
| Operating income | -1.4 | -7.6 | -6.3 | -4.7 | -3.8 | -11.7 | — | |
| Pre-tax income | -1.3 | -7.6 | -6.1 | -4.4 | -3.6 | -11.7 | — | |
| Net income | -1.3 | -7.4 | -5.9 | -4.3 | -3.6 | -11.7 | — | |
| Diluted EPS ($) | — | -0.02 | -1.19 | -0.87 | -0.72 | -2.37 | — | |
| Diluted shares (mn) | — | 486.6 | 494.5 | 494.5 | 494.5 | 494.6 | — |
USD millions · SEC XBRL
Regencell Bioscience Holdings Ltd — questions
- What is Regencell Bioscience Holdings Ltd's net income?
- -$11.7M over the twelve months to .
Every figure on this page comes from Regencell Bioscience Holdings Ltd's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.